Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Common Equity (2016 - 2025)

Historic Common Equity for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $1.0 billion.

  • Integra Lifesciences Holdings' Common Equity fell 3180.97% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 3180.97%. This contributed to the annual value of $1.5 billion for FY2024, which is 268.31% down from last year.
  • Per Integra Lifesciences Holdings' latest filing, its Common Equity stood at $1.0 billion for Q3 2025, which was down 3180.97% from $1.0 billion recorded in Q2 2025.
  • Integra Lifesciences Holdings' 5-year Common Equity high stood at $1.8 billion for Q4 2022, and its period low was $1.0 billion during Q3 2025.
  • For the 5-year period, Integra Lifesciences Holdings' Common Equity averaged around $1.6 billion, with its median value being $1.6 billion (2023).
  • In the last 5 years, Integra Lifesciences Holdings' Common Equity soared by 1674.34% in 2021 and then tumbled by 3229.93% in 2025.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' Common Equity stood at $1.7 billion in 2021, then increased by 7.1% to $1.8 billion in 2022, then dropped by 12.0% to $1.6 billion in 2023, then fell by 2.68% to $1.5 billion in 2024, then tumbled by 32.86% to $1.0 billion in 2025.
  • Its Common Equity stands at $1.0 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $1.5 billion for Q1 2025.